Vireo Capital Research · Coverage Universe
Research Reports
Full equity initiations with DCF models, comparable company analysis, and a named analyst behind every rating.
6
Buy
2
Hold
4
Sell
Showing 12 reports
GitLab Inc.
Target
$39.1
-21.5%
We revise GitLab to a SELL with a USD 39.10 target against USD 49.83. The operating story improved materially in Q2 FY2027: revenue up 21%, net ARR growth accelerating to 42%, and raised full-year guidance. The issue is now valuation rather than near-term execution. Even crediting the long-term margin framework, with FCF approaching USD 724 million by FY2031, the current price already discounts more than the model supports.
EQT Corporation
Target
$69.95
+32.5%
EQT is a BUY with a USD 69.95 target, about 32.5% upside. The obvious concern is weak natural gas prices through 2026, with spot dipping below USD 3/MMBtu. That risk is real, but the market still values EQT as a traditional gas producer and misses how much it has changed: a stronger balance sheet, the pipeline system bought back in-house, and exposure to two demand drivers just beginning to develop, LNG exports and AI-driven power demand.
NVIDIA Corporation
Target
$186
-14.5%
A speculative sell with a fair value of USD 186 against USD 217.55. The rating does not rest on the business being weak, the quarter being poor, or the shares being expensive on near-term earnings. Almost everything is in NVIDIA's favor: Q2 revenue of USD 96.2bn grew 106%, and Vera Rubin is the fastest product ramp in the company's history. It rests on one thing, that the market is paying for growth to last longer than we are willing to underwrite.
Citigroup, Inc.
Target
$160
+20.4%
Citigroup trades at 1.32x tangible book value; JPMorgan trades at 3.27x. Both are money center banks in the same rate environment and regulatory regime. JPMorgan earns a higher return, which justifies some premium, but not one that size, and Citigroup's Q2 2026 ROTCE of 13.0% shows why. That sits at the top of management's guidance range. Jane Fraser's transformation is working, and the discount is too wide.
JPMorgan Chase & Co.
Target
$323
-11.0%
JPMorgan is the best-run large bank in the world, and we are initiating with a SELL. Nothing here disputes the franchise; the rating is about price and the durability of the return, not quality. Q2 2026 was extraordinary, up 28% on revenue and 41% on net income, but USD 4.2 billion of after-tax one-off gains flattered the headline, and a 29% ROTCE is not the through-cycle rate. At 3.2x tangible book, the stock already prices in the peak.
NuScale Power Corporation
Target
$7
-25.7%
NuScale generated USD 75,000 in revenue in Q2 2026 while burning USD 186 million in cash, roughly USD 2,500 spent for every dollar of revenue. Revenue has declined from USD 37 million in FY2024 to near-zero, while cash burn has compounded. The stock trades at about 44x a FY2026 consensus revenue estimate that Q2 has made nearly impossible to hit. The rating is SELL.
Kraken Robotics Inc.
Target
$7
+47.4%
Kraken Robotics is not a speculative bet on a technology that might one day find customers. It already has them. USD 234 million in confirmed 2026 product orders in subsea defence and autonomy exceeds the full-year revenue guidance midpoint before the year is half over, a backlog-to-guidance ratio above 1.0x. The transformational Covelya acquisition, closed July 2 for USD 441 million, roughly tripled the revenue base. (OTCQB: KRKNF; TSX-V: PNG.)
CVS Health Corporation
Target
$91
-5.4%
The Aetna recovery is real: adjusted operating income is up roughly USD 4.8B from the FY2024 trough, and management has raised full-year EPS guidance three times. But we question the durability of the beat. A large slice of the Q2 margin improvement came from one-off prior-year reserve releases rather than sustainable underwriting gains, while commercial membership is shrinking and Medicare Advantage star ratings have slipped. At roughly USD 96 the stock already prices in a clean recovery, so the rating is HOLD.
Pfizer Inc.
Target
$34
+27.7%
The market is pricing Pfizer as a COVID company in permanent decline. At 8.5x forward earnings with a 6.5% dividend yield, the stock implies the base pharma business has no growth ahead of it. Q2 2026 says otherwise: ex-COVID operational revenue grew 5%, Eliquis rose 19%, and newer products grew 18%. The COVID drag is nearly finished, and the underlying business is growing even if the headlines obscure it.
Tesla, Inc.
Target
$430
+30.9%
A speculative rating. Tesla trades at roughly 170x forward earnings, and this call rests on scenario-weighted probabilities, not a traditional DCF. Tesla is no longer primarily a car company: the thesis rides on Optimus reaching commercial leasing, Cybercab scaling across US cities, and FSD subscribers growing from 1.48 million toward six million by 2028. Loss of capital on the downside scenario is a real possibility.
Microsoft Corporation
Target
$504
+3.1%
Microsoft just reported one of its best quarters ever, and we still rate it HOLD. Four years of extraordinary operating progress have produced almost no additional free cash, because the capital programme absorbed all of it. The recent capex guidance cut is the first evidence of discipline and the swing factor for the thesis. Our fair value is USD 504 against USD 488.63 today.
The Coca-Cola Company
Target
$93.53
+7.5%
We upgrade Coca-Cola to BUY with a fair value near USD 94 against USD 87 today. The dividend stream, backed by 64 consecutive years of increases, is the better anchor for valuation than a five-year earnings model. The volume recovery looks durable: Q2 volume rose 5% while price/mix still held at +2%, led by India, China, the US, and Brazil.
All reports are produced for educational purposes only and do not constitute investment advice. Price targets reflect analyst estimates as of the report date.